{"pmid":32446698,"title":"Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.","text":["Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.","Gastroenterology","Freedberg, Daniel E","Conigliaro, Joseph","Wang, Timothy C","Tracey, Kevin J","Callahan, Michael V","Abrams, Julian A","Sobieszczyk, Magdalena E","Markowitz, David D","Gupta, Aakriti","O'Donnell, Max R","Li, Jianhua","Tuveson, David A","Jin, Zhezhen","Turner, William C","Landry, Donald W","32446698"],"journal":"Gastroenterology","authors":["Freedberg, Daniel E","Conigliaro, Joseph","Wang, Timothy C","Tracey, Kevin J","Callahan, Michael V","Abrams, Julian A","Sobieszczyk, Magdalena E","Markowitz, David D","Gupta, Aakriti","O'Donnell, Max R","Li, Jianhua","Tuveson, David A","Jin, Zhezhen","Turner, William C","Landry, Donald W"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32446698","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1053/j.gastro.2020.05.053","keywords":["sars-cov-2","coronavirus 2019","famotidine","histamine-2 receptor antagonists"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667698385985994752,"score":9.490897,"similar":[{"pmid":32499303,"title":"Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.","text":["Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.","OBJECTIVE: Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient reported outcome measures in non-hospitalised patients with COVID-19 who self-administered high-dose famotidine orally. DESIGN: Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, famotidine use, drug-related side effects, temperature measurements, oxygen saturations and symptom scores were obtained using questionnaires and telephone interviews. Based on a National Institute of Health (NIH)-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches and anosmia) and general unwellness on a four-point ordinal scale modelled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalised symptom scores were statistically compared. RESULTS: Ten consecutive patients with COVID-19 who self-administered high-dose oral famotidine were identified. The most frequently used famotidine regimen was 80 mg three times daily (n=6) for a median of 11 days (range: 5-21 days). Famotidine was well tolerated. All patients reported marked improvements of disease related symptoms after starting famotidine. The combined symptom score improved significantly within 24 hours of starting famotidine and peripheral oxygen saturation (n=2) and device recorded activity (n=1) increased. CONCLUSIONS: The results of this case series suggest that high-dose oral famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.","Gut","Janowitz, Tobias","Gablenz, Eva","Pattinson, David","Wang, Timothy C","Conigliaro, Joseph","Tracey, Kevin","Tuveson, David","32499303"],"abstract":["OBJECTIVE: Treatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient reported outcome measures in non-hospitalised patients with COVID-19 who self-administered high-dose famotidine orally. DESIGN: Patients were enrolled consecutively after signing written informed consent. Data on demographics, COVID-19 diagnosis, famotidine use, drug-related side effects, temperature measurements, oxygen saturations and symptom scores were obtained using questionnaires and telephone interviews. Based on a National Institute of Health (NIH)-endorsed Protocol to research Patient Experience of COVID-19, we collected longitudinal severity scores of five symptoms (cough, shortness of breath, fatigue, headaches and anosmia) and general unwellness on a four-point ordinal scale modelled on performance status scoring. All data are reported at the patient level. Longitudinal combined normalised symptom scores were statistically compared. RESULTS: Ten consecutive patients with COVID-19 who self-administered high-dose oral famotidine were identified. The most frequently used famotidine regimen was 80 mg three times daily (n=6) for a median of 11 days (range: 5-21 days). Famotidine was well tolerated. All patients reported marked improvements of disease related symptoms after starting famotidine. The combined symptom score improved significantly within 24 hours of starting famotidine and peripheral oxygen saturation (n=2) and device recorded activity (n=1) increased. CONCLUSIONS: The results of this case series suggest that high-dose oral famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19."],"journal":"Gut","authors":["Janowitz, Tobias","Gablenz, Eva","Pattinson, David","Wang, Timothy C","Conigliaro, Joseph","Tracey, Kevin","Tuveson, David"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32499303","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/gutjnl-2020-321852","keywords":["covid-19","covid-19 symptoms","famotidine","proms","sars-cov-2","coronavirus","outpatients"],"e_drugs":["Famotidine","Histamine"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668804508790030337,"score":102.46203},{"pmid":32462179,"title":"Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study.","text":["Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study.","Blood","Tremblay, Douglas","van Gerwen, Maaike","Alsen, Mathilda","Thibaud, Santiago","Kessler, Alaina Justine","Venugopal, Sangeetha","Makki, Iman","Qin, Qian","Dharmapuri, Sirish","Jun, Tomi","Bhalla, Sheena","Berwick, Shana","Feld, Jonathan","Mascarenhas, John","Troy, Kevin","Cromwell, Caroline","Dunn, Andrew","Oh, William K","Naymagon, Leonard","32462179"],"journal":"Blood","authors":["Tremblay, Douglas","van Gerwen, Maaike","Alsen, Mathilda","Thibaud, Santiago","Kessler, Alaina Justine","Venugopal, Sangeetha","Makki, Iman","Qin, Qian","Dharmapuri, Sirish","Jun, Tomi","Bhalla, Sheena","Berwick, Shana","Feld, Jonathan","Mascarenhas, John","Troy, Kevin","Cromwell, Caroline","Dunn, Andrew","Oh, William K","Naymagon, Leonard"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462179","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1182/blood.2020006941","topics":["Treatment"],"weight":1,"_version_":1668079521525399552,"score":90.39533},{"pmid":32503812,"title":"Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study.","text":["Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study.","INTRODUCTION: With intense deficiency of medical resources during COVID-19 pandemic, risk stratification is of strategic importance. Blood glucose level is an important risk factor for the prognosis of infection and critically ill patients. We aimed to investigate the prognostic value of blood glucose level in patients with COVID-19. RESEARCH DESIGN AND METHODS: We collected clinical and survival information of 2041 consecutive hospitalized patients with COVID-19 from two medical centers in Wuhan. Patients without available blood glucose level were excluded. We performed multivariable Cox regression to calculate HRs of blood glucose-associated indexes for the risk of progression to critical cases/mortality among non-critical cases, as well as in-hospital mortality in critical cases. Sensitivity analysis were conducted in patient without diabetes. RESULTS: Elevation of admission blood glucose level was an independent risk factor for progression to critical cases/death among non-critical cases (HR=1.30, 95% CI 1.03 to 1.63, p=0.026). Elevation of initial blood glucose level of critical diagnosis was an independent risk factor for in-hospital mortality in critical cases (HR=1.84, 95% CI 1.14 to 2.98, p=0.013). Higher median glucose level during hospital stay or after critical diagnosis (>/=6.1 mmol/L) was independently associated with increased risks of progression to critical cases/death among non-critical cases, as well as in-hospital mortality in critical cases. Above results were consistent in the sensitivity analysis in patients without diabetes. CONCLUSIONS: Elevation of blood glucose level predicted worse outcomes in hospitalized patients with COVID-19. Our findings may provide a simple and practical way to risk stratify COVID-19 inpatients for hierarchical management, particularly where medical resources are in severe shortage during the pandemic.","BMJ Open Diabetes Res Care","Wu, Jianfeng","Huang, Jianqiang","Zhu, Guochao","Wang, Qiongya","Lv, Qingquan","Huang, Ying","Yu, Yang","Si, Xiang","Yi, Hui","Wang, Cuiping","Liu, Yihao","Xiao, Han","Zhou, Qian","Liu, Xin","Yang, Daya","Guan, Xiangdong","Li, Yanbing","Peng, Sui","Sung, Joseph","Xiao, Haipeng","32503812"],"abstract":["INTRODUCTION: With intense deficiency of medical resources during COVID-19 pandemic, risk stratification is of strategic importance. Blood glucose level is an important risk factor for the prognosis of infection and critically ill patients. We aimed to investigate the prognostic value of blood glucose level in patients with COVID-19. RESEARCH DESIGN AND METHODS: We collected clinical and survival information of 2041 consecutive hospitalized patients with COVID-19 from two medical centers in Wuhan. Patients without available blood glucose level were excluded. We performed multivariable Cox regression to calculate HRs of blood glucose-associated indexes for the risk of progression to critical cases/mortality among non-critical cases, as well as in-hospital mortality in critical cases. Sensitivity analysis were conducted in patient without diabetes. RESULTS: Elevation of admission blood glucose level was an independent risk factor for progression to critical cases/death among non-critical cases (HR=1.30, 95% CI 1.03 to 1.63, p=0.026). Elevation of initial blood glucose level of critical diagnosis was an independent risk factor for in-hospital mortality in critical cases (HR=1.84, 95% CI 1.14 to 2.98, p=0.013). Higher median glucose level during hospital stay or after critical diagnosis (>/=6.1 mmol/L) was independently associated with increased risks of progression to critical cases/death among non-critical cases, as well as in-hospital mortality in critical cases. Above results were consistent in the sensitivity analysis in patients without diabetes. CONCLUSIONS: Elevation of blood glucose level predicted worse outcomes in hospitalized patients with COVID-19. Our findings may provide a simple and practical way to risk stratify COVID-19 inpatients for hierarchical management, particularly where medical resources are in severe shortage during the pandemic."],"journal":"BMJ Open Diabetes Res Care","authors":["Wu, Jianfeng","Huang, Jianqiang","Zhu, Guochao","Wang, Qiongya","Lv, Qingquan","Huang, Ying","Yu, Yang","Si, Xiang","Yi, Hui","Wang, Cuiping","Liu, Yihao","Xiao, Han","Zhou, Qian","Liu, Xin","Yang, Daya","Guan, Xiangdong","Li, Yanbing","Peng, Sui","Sung, Joseph","Xiao, Haipeng"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503812","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1136/bmjdrc-2020-001476","keywords":["blood glucose","clinical study","infections"],"locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Glucose"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668892488332476417,"score":52.931316},{"pmid":32446795,"title":"Association of Diabetes Mellitus with Disease Severity and Prognosis in COVID-19: A Retrospective Cohort Study.","text":["Association of Diabetes Mellitus with Disease Severity and Prognosis in COVID-19: A Retrospective Cohort Study.","The 2019 novel coronavirus disease (COVID-19) emerged in Wuhan, China, and was characterized as a pandemic by the World Health Organization. Diabetes is an established risk associated with poor clinical outcomes, but the association of diabetes with COVID-19 has not been reported yet. METHODS: In this cohort study, we retrospectively reviewed 258 consecutive hospitalized COVID-19 patients with or without diabetes at the West Court of Union Hospital in Wuhan, China, recruited from January 29 to February 12, 2020. The clinical features, treatment strategies and prognosis data were collected and analyzed. Prognosis was followed up until March 12, 2020. RESULTS: Of the 258 hospitalized patients (63 with diabetes) with COVID-19, the median age was 64 years (range 23-91), and 138 (53.5%) were male. Common symptoms included fever (82.2%), dry cough (67.1%), polypnea (48.1%), and fatigue (38%). Patients with diabetes had significantly higher leucocyte and neutrophil counts, and higher levels of fasting blood glucose, serum creatinine, urea nitrogen and creatine kinase isoenzyme MB at admission compared with those without diabetes. COVID-19 patients with diabetes were more likely to develop severe or critical disease conditions with more complications, and had higher incidence rates of antibiotic therapy, non-invasive and invasive mechanical ventilation, and death (11.1% vs. 4.1%). Cox proportional hazard model showed that diabetes (adjusted hazard ratio [aHR]=3.64; 95% confidence interval [CI]: 1.09, 12.21) and fasting blood glucose (aHR=1.19; 95% CI: 1.08, 1.31) were associated with the fatality due to COVID-19, adjusting for potential confounders. CONCLUSIONS: Diabetes mellitus is associated with increased disease severity and a higher risk of mortality in patients with COVID-19.","Diabetes Res Clin Pract","Zhang, Yan","Cui, Yanhui","Shen, Minxue","Zhang, Jianchu","Liu, Ben","Dai, Minhui","Chen, Lingli","Han, Duoduo","Fan, Yifei","Zeng, Yanjun","Li, Wen","Lin, Fengyu","Li, Sha","Chen, Xiang","Pan, Pinhua","32446795"],"abstract":["The 2019 novel coronavirus disease (COVID-19) emerged in Wuhan, China, and was characterized as a pandemic by the World Health Organization. Diabetes is an established risk associated with poor clinical outcomes, but the association of diabetes with COVID-19 has not been reported yet. METHODS: In this cohort study, we retrospectively reviewed 258 consecutive hospitalized COVID-19 patients with or without diabetes at the West Court of Union Hospital in Wuhan, China, recruited from January 29 to February 12, 2020. The clinical features, treatment strategies and prognosis data were collected and analyzed. Prognosis was followed up until March 12, 2020. RESULTS: Of the 258 hospitalized patients (63 with diabetes) with COVID-19, the median age was 64 years (range 23-91), and 138 (53.5%) were male. Common symptoms included fever (82.2%), dry cough (67.1%), polypnea (48.1%), and fatigue (38%). Patients with diabetes had significantly higher leucocyte and neutrophil counts, and higher levels of fasting blood glucose, serum creatinine, urea nitrogen and creatine kinase isoenzyme MB at admission compared with those without diabetes. COVID-19 patients with diabetes were more likely to develop severe or critical disease conditions with more complications, and had higher incidence rates of antibiotic therapy, non-invasive and invasive mechanical ventilation, and death (11.1% vs. 4.1%). Cox proportional hazard model showed that diabetes (adjusted hazard ratio [aHR]=3.64; 95% confidence interval [CI]: 1.09, 12.21) and fasting blood glucose (aHR=1.19; 95% CI: 1.08, 1.31) were associated with the fatality due to COVID-19, adjusting for potential confounders. CONCLUSIONS: Diabetes mellitus is associated with increased disease severity and a higher risk of mortality in patients with COVID-19."],"journal":"Diabetes Res Clin Pract","authors":["Zhang, Yan","Cui, Yanhui","Shen, Minxue","Zhang, Jianchu","Liu, Ben","Dai, Minhui","Chen, Lingli","Han, Duoduo","Fan, Yifei","Zeng, Yanjun","Li, Wen","Lin, Fengyu","Li, Sha","Chen, Xiang","Pan, Pinhua"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32446795","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.diabres.2020.108227","keywords":["covid-19","diabetes mellitus","sars-cov-2","prognosis"],"locations":["Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667698385937760258,"score":51.469376},{"pmid":32405232,"pmcid":"PMC7219367","title":"Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic.","text":["Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic.","Background: The coronavirus disease 2019 (COVID-19) pandemic has increased burden on healthcare systems with subsequent reductions in non-emergent hospitalizations and procedures. While there are widespread reports of intentional reductions in elective hospitalizations, trends in urgent or emergent hospitalizations including heart failure (HF) hospitalizations have not been adequately characterized. Methods: We evaluated trends of HF hospitalizations before and during the COVID-19 pandemic at the University of Mississippi Medical Center using electronic health records and discharge database. We also compared HF hospitalization trends during the same time frame in 2019 to account for seasonal variation in HF presentations. Results: Prior to the COVID-19 pandemic in our medical center, a mean of 30 patients per week were admitted with a principal diagnosis of HF. After the first case of COVID-19 was diagnosed in Mississippi, there was a sharp 50% decline in the number of HF hospitalizations that declined even further after a \"state of emergency\" was declared in Mississippi. Conclusions: Based on observations from a large academic medical center, there has been a significant reduction in the number of patients hospitalized for HF during the COVID-19 pandemic. Further investigation of these trends is warranted to determine the effects of the COVID-19 pandemic on long-term HF outcomes.","J Card Fail","Hall, Michael E","Vaduganathan, Muthiah","Khan, Muhammad Shahzeb","Papadimitriou, Lampros","Long, Robert C","Hernandez, Gabriel A","Moore, Charles K","Lennep, Brandon W","McMullan, Michael R","Butler, Javed","32405232"],"abstract":["Background: The coronavirus disease 2019 (COVID-19) pandemic has increased burden on healthcare systems with subsequent reductions in non-emergent hospitalizations and procedures. While there are widespread reports of intentional reductions in elective hospitalizations, trends in urgent or emergent hospitalizations including heart failure (HF) hospitalizations have not been adequately characterized. Methods: We evaluated trends of HF hospitalizations before and during the COVID-19 pandemic at the University of Mississippi Medical Center using electronic health records and discharge database. We also compared HF hospitalization trends during the same time frame in 2019 to account for seasonal variation in HF presentations. Results: Prior to the COVID-19 pandemic in our medical center, a mean of 30 patients per week were admitted with a principal diagnosis of HF. After the first case of COVID-19 was diagnosed in Mississippi, there was a sharp 50% decline in the number of HF hospitalizations that declined even further after a \"state of emergency\" was declared in Mississippi. Conclusions: Based on observations from a large academic medical center, there has been a significant reduction in the number of patients hospitalized for HF during the COVID-19 pandemic. Further investigation of these trends is warranted to determine the effects of the COVID-19 pandemic on long-term HF outcomes."],"journal":"J Card Fail","authors":["Hall, Michael E","Vaduganathan, Muthiah","Khan, Muhammad Shahzeb","Papadimitriou, Lampros","Long, Robert C","Hernandez, Gabriel A","Moore, Charles K","Lennep, Brandon W","McMullan, Michael R","Butler, Javed"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405232","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.cardfail.2020.05.005","keywords":["covid-19","coronavirus 2019","heart failure"],"locations":["Mississippi","Mississippi"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666802845393879041,"score":50.487957}]}